In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 12 ( 2022-12-30), p. e0278963-
Abstract:
Remdesivir (RDV) is the only antiviral drug approved for COVID-19 therapy by the FDA. Another drug LAGEVRIO™ (molnupiravir) though has not been approved yet by FDA but has been authorized on December 23, 2021, for emergency use to treat adults with mild-to moderate COVID-19 symptoms and for whom alternative COVID-19 treatment options are not clinically appropriate. The fact is that the efficacy of RDV is, however, limited in vivo though it is highly promising in vitro against SARS-CoV-2 virus. In this paper we are focusing on the action mechanism of RDV and how it can be improved in vivo . The stability of RDV alone and on encapsulation with our platform technology based polymer NV-387 (NV-CoV-2), were compared in presence of plasma in vitro and in vivo . Furthermore, a non-clinical pharmacology study of NV-CoV-2 (Polymer) and NV CoV-2 (Polymer encapsulated Remdesivir ) in both NL-63 infected and uninfected rats was done. In addition, the antiviral activity of NV-CoV-2 and NV-CoV-2-R was compared with RDV in a cell culture study. The results are (i) NV-CoV-2 polymer encapsulation protects RDV from plasma-mediated catabolism in both in vitro and in vivo , studies; (ii) Body weight measurements of the normal (uninfected) rats after administration of the test materials (NV-CoV-2 and NV-CoV-2-R) showed no toxic effects. (iii) Body weight measurements and survival rates of the NL-63 infected rats were similar to the uninfected rats after treatment with NV-CoV-2 and NV-CoV-2-R. Overall, the efficacy as an antiviral regimens were found in this order as below; NV-CoV-2-R 〉 NV-CoV-2 〉 RDV. Our platform technology based NV-387-encapsulated-RDV (NV-CoV-2-R) drug has a dual effect against different variants of the coronaviruses. First, NV-CoV-2 is an antiviral regimen. Secondly, RDV is protected from plasma-mediated degradation in transit. All together, NV-CoV-2-R is the safest and efficient regimen against COVID-19.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0278963
DOI:
10.1371/journal.pone.0278963.g001
DOI:
10.1371/journal.pone.0278963.g002
DOI:
10.1371/journal.pone.0278963.g003
DOI:
10.1371/journal.pone.0278963.g004
DOI:
10.1371/journal.pone.0278963.g005
DOI:
10.1371/journal.pone.0278963.g006
DOI:
10.1371/journal.pone.0278963.g007
DOI:
10.1371/journal.pone.0278963.t001
DOI:
10.1371/journal.pone.0278963.t002
DOI:
10.1371/journal.pone.0278963.t003
DOI:
10.1371/journal.pone.0278963.t004
DOI:
10.1371/journal.pone.0278963.t005
DOI:
10.1371/journal.pone.0278963.t006
DOI:
10.1371/journal.pone.0278963.s001
DOI:
10.1371/journal.pone.0278963.s002
DOI:
10.1371/journal.pone.0278963.r001
DOI:
10.1371/journal.pone.0278963.r002
DOI:
10.1371/journal.pone.0278963.r003
DOI:
10.1371/journal.pone.0278963.r004
DOI:
10.1371/journal.pone.0278963.r005
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Permalink